Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Two Generations of Self-Expandable Transcatheter Heart Valves in Nine Surgical Valves: An In Vitro Study.
J Cardiovasc Dev Dis
August 2024
Department of Cardiac and Thoracic Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23538 Lubeck, Germany.
(1) Background: This study aimed to analyse the hydrodynamic performance of two generations of self-expanding transcatheter heart valves (THV) as a valve-in-valve (ViV) in different surgical aortic valve (SAV) models under standardised conditions. The nitinol-based Evolut R valve is frequently used in ViV procedures. It is unclear whether its successor, the Evolut PRO, is superior in ViV procedures, particularly considering the previously implanted SAV model.
View Article and Find Full Text PDFRestricted cusp motion in newly implanted tricuspid bioprostheses: Incidence, predictors, and impact on survival.
J Thorac Cardiovasc Surg
May 2024
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Article Synopsis
- - The study aimed to explore the occurrence of restricted cusp motion (RCM) during bioprosthetic tricuspid valve replacement (TVR) and its risk factors and effects on patient outcomes.
- - Out of 476 patients analyzed from 2012 to 2022, 31.5% exhibited RCM, with 13.2% having complete immobility and 18.3% showing limited movement of the valve cusp.
- - The research found that certain factors, like the type of valve used and patient-specific measurements, significantly influenced the likelihood of RCM, which was linked to a higher mortality risk, highlighting the importance of careful prosthesis selection.
Successful Reversal of Late, Severe Thrombotic Bioprosthetic Mitral Valve Stenosis With Anticoagulation Therapy.
Cureus
February 2024
Cardiology, Cardiovascular Wellness Center, Homestead, USA.
Late bioprosthetic valve thrombosis (bPVT) is a rare and potentially life-threatening complication following valve replacement with thrombus formation leading mostly to valvular stenosis or embolic phenomena. Clinically, it manifests as symptoms of fatigue, dyspnea, or reduced exercise capacity. The existing treatment guidelines lack clear recommendations for managing this specific presentation.
View Article and Find Full Text PDFDifferential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model.
Bioengineering (Basel)
July 2023
Infectious Diseases and Transplantation Division, Institut d'Investigació Biomèdica de Bellvitge [IDIBELL], L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Structural valve deterioration (SVD) of bioprosthetic heart valves (BHVs) has great clinical and economic consequences. Notably, immunity against BHVs plays a major role in SVD, especially when implanted in young and middle-aged patients. However, the complex pathogenesis of SVD remains to be fully characterized, and analyses of commercial BHVs in standardized-preclinical settings are needed for further advancement.
View Article and Find Full Text PDFBioprosthetic Valve Remodeling in Nonfracturable Surgical Valves: Impact on THV Expansion and Hydrodynamic Performance.
JACC Cardiovasc Interv
July 2023
Centre for Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver, Canada; Cardiovascular Translational Laboratory, Providence Research and Centre for Heart Lung Innovation, Vancouver, Canada; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
Background: There are limited data on the effect of bioprosthetic valve remodeling (BVR) on transcatheter heart valve (THV) expansion and function following valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) in a nonfracturable surgical heart valve (SHV).
Objectives: This study sought to assess the impact of BVR of nonfracturable SHVs on THVs after VIV implantation.
Methods: VIV TAVR was performed using 23-mm SAPIEN3 (S3, Edwards Lifesciences) or 23/26-mm Evolut Pro (Medtronic) THVs implanted in 21/23-mm Trifecta (Abbott Structural Heart) and 21/23-mm Hancock (Medtronic) SHVs with BVR performed with a noncompliant TRUE balloon (Bard Peripheral Vascular Inc).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!